Biolargo, INC 10-Q quarterly reports

BioLargo, Inc. announced its Q2 2026 financial results, revealing a significant decrease in revenue and a widening net loss, alongside a negative working capital position.

BioLargo reports a substantial 75% revenue decline in Q3 2025 and a $3.8 million credit loss due to a customer default, raising significant going concern doubts.

BioLargo, Inc. reported a significant 38% decline in total revenue and a widened net loss for the six months ended June 30, 2025, raising substantial doubt about its ability to continue as a going concern.

BioLargo's Q1 2025 revenue decreased by 31% compared to Q1 2024, primarily due to lower sales of its private-label pet odor control product, while the company continues to invest in the development and commercialization of its cleantech technologies.

BioLargo, Inc. saw a significant increase in revenue during the third quarter of 2024, primarily driven by sales of its private-label pet odor control product.

BioLargo Inc. saw a significant increase in revenue during the second quarter of 2024, primarily driven by sales of its private-label pet odor control product.

BioLargo's Q1 2024 revenue increased by 27% year-over-year, primarily driven by sales of its private-label pet odor control product, while the company continues to develop its environmental and medical technologies.